Impact of fatty acid desaturase 1 (FADS1) on chronic kidney disease via very low-density lipoprotein: A drug target–related mediation Mendelian randomization study
Journal of Clinical Lipidology · 2025
DOI: 10.1016/j.jacl.2025.06.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Yongdi Zuo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, West China Hospital of Sichuan University, Chengdu, China (Dr Zuo, Chen, Drs He, Du, and Tang). Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Mendelian Randomization Analysis, Fatty Acid Desaturases, Lipoproteins, VLDL. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
BACKGROUND: Chronic kidney disease (CKD) is a globally prevalent condition and still lacks effective specific medications. Metabolic dysregulation plays a crucial role in CKD. OBJECTIVE: To Identify new potential targets for CKD through metabolites and their regulatory genes. METHODS: A total of 233 metabolites from the genome-wide association studies (GWAS) Catalog were utilized for Mendelian randomization (MR) with CKD. External validation was conducted from UK Biobank. Cis-eQTL of genes related to very low-density lipoprotein (VLDL) were selected for MR with CKD and metabolites. The total effect of the fatty acid desaturase 1 gene (FADS1) on CKD and metabolite-mediated effects were calculated. Bulk RNA-seq were used to validate FADS1 expression in the kidney tissues of patients with CKD. RESULTS: The cholesteryl esters to total lipids ratio in medium VLDL (odds ratio [OR] = 0.84; P.adj = .039) and total cholesterol to total lipids ratio in small VLDL (OR = 0.84; P.adj = .003) were protective factors for CKD, whereas the triglycerides to total lipids ratio in small VLDL (OR = 1.18; P.adj = .009) and the triglycerides to total lipids ratio in very small VLDL (OR = 1.1; P.adj < .001) were risk factors. They mediated the risk of CKD by FADS1 (OR = 1.1; P.adj = .001), and mediation effects of 21.17%, 10.43%, 23.52%, and 29.96%, respectively, were obtained. The differential expression of FADS1 was observed in the kidney tissues of patients with CKD. CONCLUSION: FADS1 is a risk factor for CKD and a novel therapeutic target. Four metabolites mediate the detrimental effect of FADS1 in CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, West China Hospital of Sichuan University, Chengdu, China (Dr Zuo, Chen, Drs He, Du, and Tang).
- Department of Nephrology, West China Hospital of Sichuan University, Chengdu, China (Dr Zuo, Chen, Drs He, Du, and Tang); West China School of Medicine, Sichuan University, Chengdu, China (Dr Tang). Electronic address:…
Förderung
- Science and Technology Department of Sichuan Province
Zitieren
APA
Zuo, Y., Chen, L., He, M., Du, J., & Tang, W. (2025). Impact of fatty acid desaturase 1 (FADS1) on chronic kidney disease via very low-density lipoprotein: A drug target–related mediation Mendelian randomization study. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.06.024
Vancouver
Zuo Y, Chen L, He M, Du J, Tang W. Impact of fatty acid desaturase 1 (FADS1) on chronic kidney disease via very low-density lipoprotein: A drug target–related mediation Mendelian randomization study. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.06.024
BibTeX
@article{Zuo2025,
author = {Zuo, Yongdi and Chen, Lei and He, Manrong and Du, Jingxue and Tang, Wanxin},
title = {Impact of fatty acid desaturase 1 (FADS1) on chronic kidney disease via very low-density lipoprotein: A drug target–related mediation Mendelian randomization study},
journal = {Journal of Clinical Lipidology},
year = {2025},
doi = {10.1016/j.jacl.2025.06.024}
}
EUVIMED